custom image

Emerging Cell Therapies:
Realizing the Vision of NextGen Cell Therapeutics

January 25-27, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET*
*Program is in development and subject to change



 Attention


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.


 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries


Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.


Apply Here


Cellular therapeutics are poised to be a next pillar of medicine along with small molecules and biologics. These living drugs have a unique capacity for more complex decision-making and therapeutic responses, potentially alleviating the need for chronic treatment. Next-generation cell therapies will need to adapt and respond to disease progression, essentially functioning as microscopic “physicians” capable of sensing, diagnosing, and eradicating disease via multifaceted mechanisms that are difficult to resist yet similar to our natural immune system. Advances in engineered T cell therapeutics are being FDA approved and are now transforming treatment plans for cancers that previously had few therapeutic options. While there have been unprecedented complete responses in a subset of hematological malignancies, the current therapies can show significant toxicity and on the other hand show a lack of efficacy in solid tumors. Beyond cancer, engineered cell therapies could have significant impact in the treatment of autoimmunity, metabolic disorders and in regenerative medicine. This conference will therefore cover next-generation cellular engineering approaches designed to tackle refractory diseases such as solid tumors, while also addressing the higher safety requirements for diseases beyond late-stage metastatic cancers. This conference brings together clinically minded cell therapists, synthetic biologists, genome and protein engineers, systems biologists, and immunologists; this combined expertise is essential to establish cells as a safe and effective therapeutic strategy across a range of diseases. Smart cellular therapeutics of the future must be easily customizable, have intrinsic control systems to prevent toxicity, and be able to overcome rapidly evolving mechanisms preventing disease resolution; this conference aims to address these topics by convening global experts across a range of relevant disciplines.

Apply Here for Free On Demand Access

Pricing:

Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD

Deadlines:

Abstract Submission:
‣ For Short Talk Consideration: Passed
‣ For Poster Booth: Passed
ePoster / SciTalk Submission: January 14, 2021*
Financial Aid Application: Passed

*Please note, abstract submission is required
in order to submit an ePoster and/or Scitalk

#VKSSmartCells21



Program Details



Speaking at this eSymposia


David Baker

University of Washington, USA


Christine E. Brown

Beckman Research Institute, City of Hope, USA


Dario Campana

National University of Singapore, Singapore


Yvonne Y. Chen

University of California, Los Angeles, USA


Tal Danino

Columbia University, USA


Tara L. Deans

University of Utah, USA


David Edward Gilham

Celyad, Belgium


Saar I. Gill

University of Pennsylvania, USA


Jane L. Grogan

Arsenal Biosciences, USA


Darrell J. Irvine

Massachusetts Institute of Technology, USA



Dan S. Kaufman

University of California, San Diego, USA


Ahmad S. Khalil

Boston University, USA


Megan K. Levings

University of British Columbia, Canada


Timothy K. Lu

Massachusetts Institute of Technology, USA


Alex Marson

University of California, San Francisco, USA


Marcela V. Maus

Harvard Medical School, USA


Miriam Merad

Mount Sinai School of Medicine, USA


David J. Mooney

Harvard University, USA


Martin Pule

University College London, UK


Aaron Ring

Yale School of Medicine, USA


Isabelle Riviere

Memorial Sloan Kettering Cancer Center, USA


Kole T. Roybal

University of California, San Francisco, USA


Barbra Sasu

Allogene Therapeutics, USA


Andrea Schietinger

Memorial Sloan Kettering Cancer Center , USA


Tatiana Segura

Duke University, USA


Matthias Stephan

Fred Hutchinson Cancer Research Center, USA


Joseph C. Sun

Memorial Sloan Kettering Cancer Center, USA






Sponsors


sponsor-carousel-astraz.png

sponsor-carousel-biolegend.png

sponsor-carousel-bluerock.png



sponsor-carousel-nektar.png

Sponsor-carousel-novo-norodisk.png

sponsor-carousel-tcr-therapeutics.png



 

sponsor-carousel-thermo-fisher.png

 




Additional Support



sponsor-carousel-Adipogen-life-sciences.png

Sponsor-carousel-American-Association-Cancer-Research.png

sponsor-carousel-bmgf.png

sponsor-carousel-DCVC-Bio.png

sponsor-carousel-nci.png

sponsor-carousel-NanoString.png

Funding for this conference was made possible (in part) by Grant No. 1R13CA254054-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.




Media-in-Kind Support


sponsor-carousel-jcb-jem.png

sponsor-carousel-embo.png

sponsor-carousel-frontiers.png

sponsor-carousel-scientist.png



#ScienceMustGoOn


This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.







The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.






Related Keystone Symposia In-Person Meetings

Explore all cancer-related meetings on the Keystone Symposia website.

custom image

custom image

custom image






Donate to Keystone Symposia


custom image